Sugammadex Accord: Uses, Dosage & Side Effects

What Is Sugammadex Accord and What Is It Used For?

Sugammadex Accord contains sugammadex sodium, a modified gamma-cyclodextrin that is used during anesthesia to reverse the muscle-relaxing effects of rocuronium or vecuronium. It is administered as an intravenous injection by an anesthesiologist and works by wrapping around the neuromuscular blocker molecules in the bloodstream so that they can no longer reach the neuromuscular junction, restoring normal muscle function within minutes.

Sugammadex Accord is a hospital-only, prescription-only medicine used in operating theatres, intensive care units, and post-anesthesia care units. It belongs to a unique pharmacological class known as selective relaxant binding agents (SRBAs) and was the first drug designed to reverse neuromuscular blockade by directly binding to the blocking agent rather than by acting on acetylcholinesterase. Sugammadex has fundamentally changed the way anesthesiologists manage muscle relaxation during surgery and emergency airway care.

During many surgical procedures, particularly abdominal, thoracic, ENT, orthopedic, and major vascular operations, patients are given neuromuscular blocking agents (also called muscle relaxants) to paralyze skeletal muscles temporarily. This facilitates tracheal intubation, allows controlled mechanical ventilation, and provides optimal surgical conditions. Rocuronium and vecuronium are two of the most widely used aminosteroid neuromuscular blockers worldwide because of their favorable onset and duration of action. However, these effects must be fully reversed before the patient wakes up, or residual paralysis can impair breathing, airway protection, and recovery.

Before sugammadex was introduced in Europe in 2008 and approved by the U.S. FDA in 2015, the standard reversal approach was a combination of an acetylcholinesterase inhibitor (typically neostigmine) and an antimuscarinic agent (such as glycopyrrolate or atropine). Although this approach usually works well, it has important limitations: reversal is relatively slow, it cannot reliably reverse deep blockade, and the muscarinic side effects (bradycardia, salivation, nausea) require co-administration of a drying agent. Sugammadex avoids these limitations by acting directly on the neuromuscular blocker itself rather than on the cholinergic synapse.

Approved Indications

Sugammadex Accord is approved by major regulatory agencies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the following uses:

• Routine reversal of moderate neuromuscular blockade induced by rocuronium or vecuronium in adults (T2 reappearance after stimulation of the adductor pollicis muscle).
• Routine reversal of deep neuromuscular blockade induced by rocuronium or vecuronium in adults (1–2 post-tetanic counts, PTC).
• Immediate reversal of rocuronium-induced neuromuscular blockade in adults, for example in a “cannot intubate, cannot ventilate” emergency scenario.
• Routine reversal of moderate blockade induced by rocuronium in children and adolescents aged 2 to 17 years.

Sugammadex is not indicated for the reversal of neuromuscular blockade induced by benzylisoquinolinium compounds such as atracurium, cisatracurium, or mivacurium, nor for the reversal of depolarizing agents such as succinylcholine. In these situations, other reversal strategies (or spontaneous recovery) are required.

Clinical Advantages Over Traditional Reversal

Sugammadex has several advantages that explain why its use has grown rapidly since its introduction:

• Speed: Full recovery typically within 1–3 minutes, compared with 10 minutes or more for neostigmine.
• Reliability even at deep blockade: Neostigmine cannot reliably reverse deep blockade; sugammadex can, at the appropriate dose.
• No anticholinergic co-therapy: No need for atropine or glycopyrrolate, avoiding dry mouth, blurred vision, and tachycardia.
• Lower incidence of residual paralysis: Post-operative residual neuromuscular blockade, a known risk factor for pulmonary complications, is significantly reduced.
• Emergency airway rescue: Sugammadex 16 mg/kg can rapidly reverse a high-dose (e.g. 1.2 mg/kg) intubating dose of rocuronium, potentially restoring spontaneous ventilation faster than spontaneous recovery from succinylcholine.

These benefits have prompted multiple professional societies, including the American Society of Anesthesiologists (ASA), the European Society of Anaesthesiology and Intensive Care (ESAIC), and the Association of Anaesthetists, to recommend routine quantitative neuromuscular monitoring and to support the use of sugammadex as part of a strategy to prevent residual neuromuscular blockade.

What Should You Know Before Taking Sugammadex Accord?

Sugammadex is administered by trained anesthesiologists or nurse anesthetists in a setting with continuous cardiorespiratory monitoring and full resuscitation facilities. Before administering it, the anesthesia team assesses kidney function, allergy history, current medications (especially hormonal contraceptives), pregnancy status, and the depth of neuromuscular blockade using quantitative monitoring.

Because Sugammadex Accord is used exclusively in the hospital setting by anesthesia professionals, most of the safety checks happen automatically as part of the preoperative assessment and intraoperative monitoring. Nevertheless, it is important for patients and caregivers to understand the contraindications, warnings, and precautions that govern its use, particularly when completing preoperative questionnaires or providing information about medications and allergies.

Contraindications

Sugammadex Accord must not be used in patients with the following conditions:

• Hypersensitivity to sugammadex or any excipient: Patients with a known allergy to sugammadex or to any of the inactive ingredients (sodium hydroxide, hydrochloric acid, water for injections) must not receive the drug. Alternative reversal strategies (neostigmine plus glycopyrrolate, or spontaneous recovery) should be used.

There are no other absolute contraindications in the EMA or FDA labeling. However, several situations require strong caution or the use of alternative strategies, discussed below.

Warnings and Precautions

The anesthesia team will consider the following warnings and precautions before and during administration of Sugammadex Accord:

• Hypersensitivity and anaphylaxis: Severe, life-threatening allergic reactions have been reported, sometimes in patients without previous exposure to sugammadex. These reactions can present as flushing, urticaria, bronchospasm, laryngeal edema, hypotension, or full anaphylaxis. Higher doses (16 mg/kg) appear to carry a slightly higher risk.
• Bradycardia and cardiac arrest: Marked bradycardia, sometimes leading to cardiac arrest, has occurred within minutes of sugammadex administration. Continuous ECG monitoring and the immediate availability of anticholinergic drugs and vasopressors are essential.
• Severe renal impairment: Sugammadex and the sugammadex–rocuronium complex are cleared almost entirely by the kidneys. Use is not recommended in patients with a creatinine clearance below 30 mL/min or those on dialysis, because of limited safety data and potential accumulation. In mild to moderate renal impairment, no dose adjustment is required.
• Coagulation effects: Sugammadex may transiently prolong activated partial thromboplastin time (aPTT) and prothrombin time (PT) in the first hour after administration. The clinical significance is usually minor but may need to be considered in patients at high bleeding risk or on anticoagulants.
• Recurrence of neuromuscular blockade: If an insufficient dose is used, residual or recurrent neuromuscular blockade may occur, particularly in patients with renal failure. Quantitative neuromuscular monitoring until full recovery is essential.
• Light anesthesia: Because sugammadex reverses paralysis so quickly, the anesthesiologist must ensure that the depth of anesthesia (hypnosis and analgesia) is adequate at the time of reversal to prevent awareness.
• Toremifene: This selective estrogen receptor modulator has a relatively high affinity for sugammadex and could theoretically displace rocuronium or vecuronium from the complex, leading to recurrence of blockade.

Patients with Specific Medical Conditions

Additional caution is warranted in the following groups:

• Severe hepatic impairment: Data are limited. Because sugammadex itself is not metabolized by the liver, dose adjustment is generally not considered necessary, but caution is advised because the underlying surgical and anesthetic risks are higher.
• Cardiac disease: In patients with known cardiac disease, continuous ECG monitoring is especially important given the reports of bradycardia and cardiac arrest.
• Pulmonary disease: Cough, bronchospasm, and post-operative respiratory events have occasionally been reported. Careful extubation criteria and continued monitoring are essential.
• Hematological disorders or anticoagulation: Small, transient changes in coagulation parameters mean the anesthesia team may time sugammadex administration around other bleeding-related concerns.

Pregnancy, Breastfeeding, and Fertility

There is limited human data on the use of sugammadex during pregnancy. Animal reproduction studies have not shown direct or indirect harmful effects. Sugammadex may be used during pregnancy only if clearly needed, typically as part of reversal after general anesthesia for urgent surgery (including caesarean section) where rocuronium or vecuronium has been used. The decision is made by the anesthesiologist on a case-by-case basis.

It is unknown whether sugammadex is excreted in human breast milk. Oral absorption of cyclodextrins is low, so a breastfed infant is unlikely to be exposed to clinically relevant levels following a single maternal dose. In most cases, breastfeeding can be resumed as soon as the mother has recovered from anesthesia and is alert enough to do so safely. You should discuss this with your anesthesiologist and, if applicable, your pediatrician.

There is no evidence that sugammadex impairs male or female fertility in humans at clinical doses.

Hormonal Contraceptive Users — Critical Patient Information

Driving and Operating Machinery

Sugammadex itself does not directly impair the ability to drive or use machines, but it is given as part of a general anesthetic. You should not drive, operate machinery, sign legal documents, or make important decisions for at least 24 hours after general anesthesia, or longer if advised by your anesthesiologist.

Important Information About Excipients

Each milliliter of Sugammadex Accord 100 mg/ml solution for injection contains less than 1 mmol sodium (23 mg) per dose at typical clinical doses, so it is essentially “sodium-free.” The solution also contains sodium hydroxide and/or hydrochloric acid to adjust the pH, and water for injections. It does not contain lactose, gluten, or preservatives.

How Does Sugammadex Accord Interact with Other Drugs?

Clinically relevant interactions with sugammadex are relatively limited because it is not metabolized and does not affect cytochrome P450 enzymes. The most important interactions are with hormonal contraceptives (reduced effectiveness), toremifene (possible displacement of rocuronium), fusidic acid (possible displacement), and with repeated doses of rocuronium or vecuronium during the same anesthetic.

Unlike many medications, sugammadex is not metabolized by the liver, does not significantly bind to plasma proteins, and has little effect on cytochrome P450 or transporter systems. Most reported drug interactions therefore involve either displacement interactions (where another drug competes with the neuromuscular blocker for the sugammadex cavity) or capturing interactions (where sugammadex binds to another drug and reduces its plasma concentration, as with hormonal contraceptives).

Anesthesiologists review the entire medication list before surgery. It is still important for patients to provide an accurate medication history, including over-the-counter products, herbal remedies, and hormonal contraceptives.

Major Interactions

The following interactions are considered clinically significant and may require additional monitoring, modified dosing, or specific patient counseling:

Minor or Theoretical Interactions

The following interactions are either theoretical, based on limited evidence, or rarely clinically significant. However, they may still be considered by the anesthesia team in individual cases:

What Is the Correct Dosage of Sugammadex Accord?

Sugammadex Accord is dosed by body weight and depth of neuromuscular blockade at the time of reversal: 2 mg/kg for moderate blockade (T2 reappearance), 4 mg/kg for deep blockade (1–2 post-tetanic counts), and 16 mg/kg for immediate reversal of rocuronium-induced blockade. It is always given as a rapid intravenous bolus and the depth of blockade is measured with a nerve stimulator.

Sugammadex Accord is for intravenous use only and is administered exclusively by anesthesiologists or other clinicians trained in anesthesia and neuromuscular monitoring. The dose is selected based on several factors: the patient’s actual body weight, the neuromuscular blocking agent used (rocuronium or vecuronium), and the depth of blockade confirmed by quantitative or qualitative nerve stimulation. Sugammadex is injected as a single intravenous bolus over about 10 seconds into an existing IV line.

Adults

How Sugammadex Is Administered

• Route: Intravenous bolus only. Never given intramuscularly, subcutaneously, or orally.
• Injection time: Single bolus over approximately 10 seconds into a flowing IV line.
• Dilution: Generally administered undiluted, but may be further diluted to 10 mg/ml in 0.9% sodium chloride or 5% glucose if necessary.
• Line care: The IV line should be flushed between administration of other medications; sugammadex is incompatible with certain drugs including verapamil, ondansetron, and ranitidine.
• Monitoring: Continuous pulse oximetry, ECG, and blood pressure monitoring during and after administration; quantitative neuromuscular monitoring until full recovery (train-of-four ratio ≥ 0.9).

Children and Adolescents

As in adults, dosing in children is based on actual body weight. Pediatric anesthesiologists use age-appropriate neuromuscular monitoring techniques and may adjust airway management accordingly.

Elderly Patients

No dose adjustment is required based on age alone. Onset of action may be slightly slower in elderly patients, but efficacy and safety are comparable to those in younger adults. Because elderly patients are more likely to have renal impairment, cardiac disease, or concomitant medications, the anesthesia team generally applies closer cardiovascular and neuromuscular monitoring.

Patients with Renal Impairment

Patients with Obesity

Sugammadex doses are calculated using actual body weight, not ideal or lean body weight. In patients with severe obesity, this is especially important to ensure effective reversal, particularly when dealing with deep or immediate reversal scenarios.

Missed Dose

Sugammadex is administered as a single intraoperative dose by the anesthesia team. Patients do not self-administer it, so the concept of a “missed dose” in the usual outpatient sense does not apply. If residual or recurrent neuromuscular blockade is detected after administration (for example, weakness, inability to hold the head up for 5 seconds, or diminished respiratory effort), the anesthesiologist may give an additional bolus and provide supportive ventilation.

Overdose

Sugammadex has a wide therapeutic index. Doses up to 96 mg/kg have been administered in volunteer studies without serious adverse effects. Accidental overdosing is managed with clinical observation and symptomatic support, including cardiovascular monitoring and, if needed, hemodialysis, which effectively removes the drug. There is no specific antidote; the complex is stable and is eliminated through the kidneys over time.

What Are the Side Effects of Sugammadex Accord?

The most frequently reported side effects of sugammadex are nausea and vomiting after surgery, which are very common. Common side effects include hypotension, bradycardia, cough, headache, and abnormal taste. Rare but serious effects include anaphylaxis, severe bradycardia, and, very rarely, cardiac arrest. The anesthesia team monitors for these reactions in real time.

Most side effects of sugammadex are mild, transient, and difficult to distinguish from the general side effects of anesthesia and surgery. Serious adverse reactions are uncommon but have been well documented in clinical trials and post-marketing surveillance. The frequency categories used below follow the MedDRA convention (very common, common, uncommon, rare, very rare, not known) as used in the European Summary of Product Characteristics.

Hypersensitivity and Anaphylaxis

Severe hypersensitivity reactions, including anaphylaxis, have been reported with sugammadex. These reactions have occurred in patients with and without previous exposure to the drug, and in some cases even in patients with no known drug allergies. The risk appears to be slightly higher at the 16 mg/kg dose used for immediate reversal. Typical features include flushing, urticaria, bronchospasm, hypotension, and angioedema. Because sugammadex is always administered in a fully monitored, resuscitation-ready environment, such reactions can be treated immediately with epinephrine, fluids, oxygen, antihistamines, and corticosteroids.

Bradycardia and Cardiac Arrest

Clinically significant bradycardia, sometimes leading to cardiac arrest, has been observed within minutes of sugammadex administration. The mechanism is not fully understood and may involve non-specific vagal or anaphylactic pathways. Continuous ECG monitoring is mandatory, and atropine or other anticholinergic/vasopressor agents are immediately available.

Effect on Hormonal Contraception

As detailed in the interactions section, sugammadex binds progestogens with enough affinity to be considered equivalent to missing one oral contraceptive dose. This is not, strictly speaking, an adverse drug reaction, but it is a clinically important consequence of sugammadex administration that patients must be counseled about before or soon after surgery.

Post-operative Residual Paralysis

Although sugammadex reduces the risk of residual paralysis compared with neostigmine-based reversal, no reversal strategy eliminates it entirely. Quantitative neuromuscular monitoring (acceleromyography, electromyography, or mechanomyography) until a train-of-four ratio of at least 0.9 is achieved is considered best practice.

How Should You Store Sugammadex Accord?

Sugammadex Accord is a hospital-only injectable that is stored in the original vial at controlled room temperature, below 30°C, protected from light. It is not dispensed to patients for home use. The shelf life and in-use stability after opening are clearly stated on the packaging and are the responsibility of hospital pharmacy and anesthesia teams.

Because Sugammadex Accord is used only in the operating theatre, intensive care unit, and other in-hospital settings, storage is managed by hospital pharmacies and anesthesia departments. Patients and caregivers never have to store it at home. However, understanding storage conditions can be useful when the medicine is used in air ambulances, mobile anesthesia units, or resource-limited settings.

• Temperature: Store below 30°C. Do not freeze.
• Packaging: Keep the vial in the outer carton to protect it from light.
• After first use: The vial is intended for single use. Any unused solution should be discarded according to local regulations for pharmaceutical waste.
• Dilution: When diluted to 10 mg/ml in 0.9% sodium chloride or 5% glucose, the solution has limited in-use stability. Follow the detailed instructions in the Summary of Product Characteristics (SmPC) and local hospital policy.
• Expiration: Do not use after the expiration date (marked “EXP”) on the vial and carton. The expiration date refers to the last day of the indicated month.
• Disposal: Unused product and waste material should be disposed of in accordance with local environmental and pharmaceutical waste regulations. Do not dispose of medicines via wastewater or household waste.

What Does Sugammadex Accord Contain?

Sugammadex Accord 100 mg/ml solution for injection contains sugammadex sodium as the active ingredient. The excipients include water for injections and sodium hydroxide and/or hydrochloric acid for pH adjustment. It does not contain preservatives, lactose, gluten, or animal-derived components.

The relatively simple formulation reflects the highly targeted design of sugammadex: it is a synthetic modified gamma-cyclodextrin whose inclusion cavity has been specifically engineered to accept the steroid nucleus of rocuronium and, to a slightly lesser extent, vecuronium.

Active Ingredient

The active substance is sugammadex sodium. Each 1 mL of solution contains 100 mg of sugammadex (as sodium salt). Vials are commonly available in 2 mL (200 mg sugammadex) and 5 mL (500 mg sugammadex) sizes; exact pack sizes vary by country.

Excipients (Inactive Ingredients)

The other ingredients in Sugammadex Accord 100 mg/ml solution for injection are:

• Water for injections — the solvent
• Hydrochloric acid (3.7%) and/or sodium hydroxide — for pH adjustment

The formulation contains no preservatives, lactose, gluten, sulfites, or animal-derived substances. It is suitable for patients with these common sensitivities, though allergy to sugammadex itself (as with any medication) remains a possibility.

Appearance and Pack Sizes

Sugammadex Accord is supplied as a clear, colorless to slightly yellowish solution in clear glass vials with rubber stoppers and aluminum/plastic flip-off closures. Typical pack sizes include cartons of 10 vials of 2 mL (200 mg) or 10 vials of 5 mL (500 mg). Not all pack sizes may be marketed in every country.

Marketing Authorization Holder

Sugammadex Accord is manufactured and distributed by Accord Healthcare S.L.U., World Trade Center, Moll de Barcelona, s/n, Edifici Est, 6a planta, 08039 Barcelona, Spain, as a generic of the originator product Bridion (Merck Sharp & Dohme). The originator product Bridion is marketed globally and serves as the reference product for regulatory filings.

Frequently Asked Questions About Sugammadex Accord